Dr. Raid M. Aljumaily, MD

Dr. Aljumaily practices at Ou Medical Center-The Children's Ho - Rad CT - HOPD in Oklahoma City, Oklahoma.

Dr. Aljumaily's NPI, 1275702417, was assigned on February 21, 2008. Dr. Aljumaily holds North Carolina license 2011-01041.

Dr. Aljumaily's primary practice is Ou Medical Center-the Children's Ho - Rad CT - HOPD, at 1200 Childrens Ave, Oklahoma City, OK 73104.

Dr. Aljumaily's primary practice is Ou Medical Center-The Children's Ho - Rad CT - HOPD in Oklahoma City, Oklahoma. Dr. Aljumaily is also affiliated with OU Health University of Oklahoma Medical Center. The medical group on file is OU Health. Dmand AI also links Dr. Aljumaily to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Aljumaily practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Aljumaily's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Aljumaily's licenses on file in 2 states: North Carolina and Massachusetts.

CMS data shows 527 Medicare services from Dr. Aljumaily across 7 procedure codes in 2024, for 204 Medicare patients. Medicare paid $39,509 for them.

CMS counts 204 Medicare patients who saw Dr. Aljumaily in 2024. The largest group is 65 to 74, with 87 patients. 75% of them have cancer, and 75% have high blood pressure. 17% are also on Medicaid. Their average risk score is 2.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Aljumaily's median patient age at 71, with 51% women.

In 2024, Dr. Aljumaily wrote 710 Medicare Part D claims for 108 patients. 76% of them were for generic drugs. CMS names the drug for 513 of them, across 15 drugs with 11 or more claims each, at $1,386,120 in total drug cost. In 2023, CMS named 601 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 77 out of 100 for Dr. Aljumaily for performance year 2024, reported as part of a group. Dr. Aljumaily accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Aljumaily to 1 clinical trial. Open Payments lists research payments to Dr. Aljumaily that name 2 trials.

CMS Open Payments shows 43 general payments to Dr. Aljumaily from 15 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 56% of the total. Boehringer Ingelheim USA, Inc. paid the most, $6,941. It also lists 35 research payments totaling $7,691 from 2017 to 2024, naming 2 clinical trials.